A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine

Phase 3

Completed

• Conditions: Chronic Hepatitis B

• Registration Number: NCT00036608
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The purpose of this clinical research study is to assess the safety and effectiveness of switching to entecavir compared to continued lamivudine in patients with chronic hepatitis B.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-01
• Study First Submitted: 2002-05-10
• Study First Submitted QC: 2002-05-11
• Study First Posted: 2002-05-13
• Primary Completion: 2005-02
• Study Completion: 2005-02
• Status Verified: 2010-01
• Disposition First Submitted: 2010-01-28
• Disposition First Submitted QC: 2010-01-28
• Disposition First Posted: 2010-02-01
• Last Update Submitted: 2011-04-07
• Last Update Posted: 2011-04-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (2)

Local investigator; 🇺🇸 Dallas, Texas, United States

Local Investigator; 🇺🇸 Richmond, Virginia, United States